AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
=== Synthesis and modification === Synthesis of the subunits occurs in the cytosol. Folding of the β-subunit is thought to be aided by the chaperone CCT (chaperonin containing tailless-complex polypeptide 1), which also prevents aggregation of folded subunits. A second chaperone, PhLP (phosducin-like protein), binds to the CCT/Gβ complex, and is phosphorylated, allowing CCT to dissociate and Gγ to bind. Finally, PhLP is released, exposing the binding site for Gα, allowing for formation of the final trimer at the endoplasmic reticulum, where it is targeted to the plasma membrane. Gγ subunits are known to be prenylated (covalently modified by the addition of lipid moieties) prior to addition to Gβ, which itself has not been found to be modified. This prenylation is thought to be involved in directing the interaction of the subunit both with membrane lipids and other proteins.
Producer Steve Lillywhite, who had gained fame with successful productions of Simple Minds and U2, was to produce Grace Under Pressure. He backed out at the last moment, however, much to the ire of Lee, Lifeson and Peart. Lee said, "Steve Lillywhite is really not a man of his word ... after agreeing to do our record, he got an offer from Simple Minds, changed his mind, blew us off ... so it put us in a horrible position." Rush eventually hired Peter Henderson to co-produce and engineer the album instead.
=== Disorders of lipoid metabolism === 272 Disorders of lipoid metabolism 272.0 Pure hypercholesterolemia Fredrickson Type IIa hyperlipoproteinemia Familial hypercholesterolemia 272.1 Pure hyperglyceridemia Hypertriglyceridemia, essential Fredrickson Type IV hyperlipoproteinemia 272.2 Hyperlipidemia, mixed Fredrickson Type IIb or III hyperlipoproteinemia Tubo-eruptive xanthoma Xanthoma tuberosum 272.3 Hyperchylomicronemia Bürger-Grütz syndrome Fredrickson type I or V hyperlipoproteinemia Hyperlipidemia, Group D Mixed hyperglyceridemia 272.4 Other and unspecified hyperlipidemia Alpha-lipoproteinemia Combined hyperlipidemia 272.5 Lipoprotein deficiencies Abetalipoproteinemia Bassen-Kornzweig syndrome High-density lipoid deficiency Hypoalphalipoproteinemia Hypobetalipoproteinemia (familial) 272.6 Lipodystrophy 272.7 Lipidoses Gaucher's disease Niemann-Pick disease Sea-blue histiocyte syndrome 272.8 Other disorders of lipoid metabolism
Sources: en.wikipedia.org
On 6 December 2014, Pudzianowski defeated the olympic veteran Paweł Nastula via unanimous decision on KSW 29's co-main event. It was his third win in a row. Pudzianowski next fought Rolles Gracie Jr. in KSW 31, on 23 May 2015 in Gdańsk, Poland. He defeated Gracie Jr. via knockout in the 1st round, winning the Knockout of the Night bonus award with the performance. At KSW 32 on 31 October 2015, Pudzianowski lost to Peter Graham via TKO in the second round. Then on 27 May 2016 at KSW 35 against Marcin Różalski, he lost also in the second round this time by guillotine choke. In his next fight in KSW 37 on 3 December 2016 Pudzianowski defeated Paweł Mikołajuw with TKO in the first round. On 27 May 2017 at KSW 39 Pudzianowski defeated Tyberiusz Kowalczyk via submission to elbow strike in the second round. Pudzianowski was expected to face James McSweeney at KSW 40 on 22 October 2017. However, after McSweeney was medically cleared, he eventually faced Jay Silva and won by majority decision. Mariusz faced Karol Bedorf on 9 June 2018 at KSW 44: The Game. He lost the bout via first round kimura. Mariusz faced Szymon Kołecki in a heavyweight bout at KSW 47 on 23 March 2019. Pudzianowski lost the fight after suffering a leg injury in the first round.
Myxedema (British English: myxoedema) is a term used synonymously with severe hypothyroidism, but also to describe a dermatological change that can occur in hypothyroidism and (rare) paradoxical cases of hyperthyroidism. In this latter sense, myxedema refers to deposition of glycosaminoglycans in the dermis, which results in swelling of the affected area. One manifestation of myxedema occurring in the lower limb is pretibial myxedema, a hallmark of Graves' disease, an autoimmune form of hyperthyroidism. Myxedema can also occur in Hashimoto thyroiditis and other long-standing forms of hypothyroidism.
==== Dirty bulking ==== "Dirty bulking" is the process of eating at a massive caloric surplus without trying to figure out the exact amount of ingested macronutrients, often done with junk food such as burgers and fries. Weightlifters who attempt to gain mass quickly with no aesthetic concerns often choose to do this. "Dirty bulking" is often favored by bodybuilders in the off-season who are looking to rapidly increase size and strength without worrying about fat gain. While it can lead to quick weight gain and increased muscle mass due to the abundance of calories, it also typically results in a significant increase in body fat. This means a more aggressive cutting phase is usually required afterward to shed the excess fat, which can be physically and mentally taxing. Additionally, consuming large amounts of processed foods high in sugar and unhealthy fats can negatively impact cardiovascular health and insulin sensitivity over time. Despite these risks, some lifters find dirty bulking psychologically easier, as it removes the pressure of strict meal planning and food tracking.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.